Expression of 11beta-hydroxysteroid dehydrogenase 2 contributes to glucocorticoid resistance in lymphoblastic leukemia cells.

@article{Sai2011ExpressionO1,
  title={Expression of 11beta-hydroxysteroid dehydrogenase 2 contributes to glucocorticoid resistance in lymphoblastic leukemia cells.},
  author={Shuji Sai and Yuichi Nakagawa and Rie Yamaguchi and Masako Suzuki and Kimiyoshi Sakaguchi and Shuichi Okada and Jonathan R Seckl and Takehiko Ohzeki and Karen E. Chapman},
  journal={Leukemia research},
  year={2011},
  volume={35 12},
  pages={1644-8}
}
Synthetic glucocorticoids (GCs) form a crucial first-line treatment for childhood acute lymphoblastic leukemia (ALL). However prolonged GC therapy frequently leads to GC-resistance with an unclear molecular mechanism. 11β-hydroxysteroid dehydrogenase (11β-HSD) 2 inactivates GCs within cells. Here, we show the association between GC sensitivity and 11β-HSD2 expression in human T-cell leukemic cell lines. 11β-HSD2 mRNA and protein levels were considerably higher in GC-resistant MOLT4F cells than… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Glucocorticoid-induced apoptosis and glucocorticoid resistance in acute lymphoblastic leukemia.

The Journal of steroid biochemistry and molecular biology • 2005
View 3 Excerpts

Similar Papers

Loading similar papers…